ACAD
Price
$22.06
Change
+$0.49 (+2.27%)
Updated
Jul 10 closing price
Capitalization
3.61B
19 days until earnings call
ARCT
Price
$14.48
Change
-$0.31 (-2.10%)
Updated
Jul 10 closing price
Capitalization
401.11M
31 days until earnings call
Interact to see
Advertisement

ACAD vs ARCT

Header iconACAD vs ARCT Comparison
Open Charts ACAD vs ARCTBanner chart's image
ACADIA Pharmaceuticals
Price$22.06
Change+$0.49 (+2.27%)
Volume$1.48M
Capitalization3.61B
Arcturus Therapeutics Holdings
Price$14.48
Change-$0.31 (-2.10%)
Volume$415.36K
Capitalization401.11M
ACAD vs ARCT Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. ARCT commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and ARCT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (ACAD: $22.06 vs. ARCT: $14.48)
Brand notoriety: ACAD and ARCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 63% vs. ARCT: 88%
Market capitalization -- ACAD: $3.61B vs. ARCT: $401.11M
ACAD [@Biotechnology] is valued at $3.61B. ARCT’s [@Biotechnology] market capitalization is $401.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileARCT’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • ARCT’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 2 TA indicator(s) are bullish while ARCT’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 2 bullish, 6 bearish.
  • ARCT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +5.30% price change this week, while ARCT (@Biotechnology) price change was +5.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

ACAD is expected to report earnings on Nov 11, 2025.

ARCT is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.61B) has a higher market cap than ARCT($401M). ACAD YTD gains are higher at: 20.218 vs. ARCT (-14.673). ACAD has higher annual earnings (EBITDA): 102M vs. ARCT (-63.92M). ACAD has more cash in the bank: 682M vs. ARCT (217M). ARCT has less debt than ACAD: ARCT (42.7M) vs ACAD (56M). ACAD has higher revenues than ARCT: ACAD (996M) vs ARCT (131M).
ACADARCTACAD / ARCT
Capitalization3.61B401M900%
EBITDA102M-63.92M-160%
Gain YTD20.218-14.673-138%
P/E Ratio16.10N/A-
Revenue996M131M760%
Total Cash682M217M314%
Total Debt56M42.7M131%
FUNDAMENTALS RATINGS
ACAD vs ARCT: Fundamental Ratings
ACAD
ARCT
OUTLOOK RATING
1..100
5512
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
46
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2695
PRICE GROWTH RATING
1..100
4245
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (46) in the Pharmaceuticals Major industry is in the same range as ACAD (62) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACAD’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ACAD (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is significantly better than the same rating for ARCT (95) in the Pharmaceuticals Major industry. This means that ACAD’s stock grew significantly faster than ARCT’s over the last 12 months.

ACAD's Price Growth Rating (42) in the Biotechnology industry is in the same range as ARCT (45) in the Pharmaceuticals Major industry. This means that ACAD’s stock grew similarly to ARCT’s over the last 12 months.

ACAD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that ACAD’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADARCT
RSI
ODDS (%)
Bearish Trend 4 days ago
60%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
58%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 4 days ago
67%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
71%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CNRCF0.05N/A
+10.93%
CANTER RES CORP.
XTRAF0.260.02
+7.35%
XTRACT ONE TECHNOLOGIES INC.
FNLIF27.63N/A
N/A
First National Financial Corp.
HELNF137.99N/A
N/A
HELVETIA PATRIA HLDG.
AAGIY34.81-0.21
-0.60%
AIA Group, Ltd.

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-2.10%
TRDA - ARCT
53%
Loosely correlated
-10.70%
RXRX - ARCT
52%
Loosely correlated
+2.24%
RGNX - ARCT
51%
Loosely correlated
-1.20%
ABCL - ARCT
51%
Loosely correlated
+9.25%
MRNA - ARCT
51%
Loosely correlated
+4.54%
More